iTeos Therapeutics, Inc. ITOS
Set alert
At close · Aug 29
52-week range unavailable
- YTD
- +32.16%
- 1 year
- -40.82%
- Open
- 10.15
- Prev close
- 10.15
- Mkt cap
- 268.52M
- Vol
- 11.01M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.15
- High
- 10.15
- Forward P/E
- -1.26
- Beta
- 1.39
- Short ratio
- 3.66
- Inst. own
- 103.92%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 8.57
- 200-d avg
- 12.79
- 1y target
- 25.00
6M chart
Signals (23)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Aug 19, 2025 | 1 year ago |
| RSI: Overbought | Jun 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
| RSI: Overbought | May 28, 2025 | 1 year ago |
| SMA: Bullish | May 13, 2025 | 1 year ago |
| MACD: Buy Signal | May 13, 2025 | 1 year ago |
| SMA: Bullish | May 8, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | Apr 30, 2025 | 1 year ago |
| SMA: Bearish | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 24, 2025 | 1 year ago |
| SMA: Bearish | Apr 23, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| RSI: Oversold | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| SMA: Bearish | Mar 13, 2025 | 1 year ago |
| SMA: Bullish | Mar 12, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
Key statistics
- Market cap
- 268.52M
- Enterprise value
- -212.10M
- Trailing P/E
- 0.00
- Forward P/E
- -1.26
- PEG ratio
- 0.00
- Price / sales
- 7.67
- Price / book
- 0.43
- EPS (TTM)
- -3.14
- Beta
- 1.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 35.00M
- Revenue growth
- 0.00%
- Free cash flow
- -90.69M
- Total cash
- 488.71M
- Total debt
- 5.53M
- Return on equity
- -19.72%
- Shares outstanding
- 36.53M
- Short % of float
- 10.05%
- 50-day average
- 8.57
- 200-day average
- 12.79
Analyst view
Consensus: strong buy
- Target (low)
- 16.00
- Target (mean)
- 25.00
- Target (high)
- 47.00
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -1.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -1.18 | -1.05 | +0.13 | +11.02% |
| Aug 8, 2024 | Jun 1, 2024 | -1.04 | -0.18 | +0.86 | +82.69% |
| Aug 8, 2024 | Jun 1, 2024 | -1.04 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -1.02 | -1.07 | -0.05 | -4.90% |
| May 10, 2024 | Mar 1, 2024 | -1.02 | — | — | — |
| Mar 6, 2024 | Dec 1, 2023 | -1.03 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Wells Fargo | main | Overweight | Overweight |
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | Wells Fargo | init | — | Overweight |
| Aug 12, 2024 | JP Morgan | main | Overweight | Overweight |
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- iteostherapeutics.com
News
- Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Crude Oil Surges Over 1%; Instil Bio Shares Plunge
- iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
- Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- Wyndham Hotels & Resorts, Olink Holding And Other Big Stocks Moving Higher On Tuesday
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Monday
- Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on ITOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOXER CAPITAL L L C | Unknown | Stock Award(Grant) | May 9, 2024 | 0 |
| CALL MATTHEW A MBA | Chief Operating Officer | Stock Award(Grant) | Dec 4, 2023 | 137,898 |
| DETHEUX MICHEL | Chief Executive Officer | Stock Award(Grant) | Dec 4, 2023 | 58,903 |
| FELTQUATE DAVID M.D., PH.D. | Officer | Stock Award(Grant) | Dec 5, 2024 | 47,000 |
| GALL MATTHEW | Chief Financial Officer | Purchase | Nov 18, 2024 | 65,429 |
| MCGRATH YVONNE | Officer | Stock Award(Grant) | Dec 4, 2023 | 31,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.63% | 3,882,549 | 28.54M | Sep 29, 2024 |
| RA Capital Management, L.P. | 8.72% | 3,184,711 | 23.41M | Sep 29, 2024 |
| Boxer Capital, LLC | 8.07% | 2,946,915 | 21.66M | Sep 29, 2024 |
| MPM Asset Management, LLC | 7.50% | 2,738,785 | 20.13M | Sep 29, 2024 |
| Tang Capital Management, LLC | 6.59% | 2,407,800 | 17.70M | Sep 29, 2024 |
| MPM BioImpact Capital LLC | 4.78% | 1,745,943 | 12.83M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.34% | 855,645 | 6.29M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.84% | 671,531 | 4.94M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.57% | 572,858 | 4.21M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.17% | 426,251 | 3.13M | Sep 29, 2024 |
| BlackRock Advantage Small Cap Core Fund | 1.11% | 405,245 | 2.98M | Aug 30, 2024 |
| Fidelity Small Cap Index Fund | 0.72% | 264,212 | 1.94M | Aug 30, 2024 |